WILMINGTON, DE — Incyte (Nasdaq: INCY) will highlight new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress in Paris, running September 17–20. Presentations will include late-breaking, oral, and poster sessions featuring clinical results for povorcitinib (INCB054707), an oral JAK1 inhibitor, and ruxolitinib cream (Opzelura®), a topical JAK1/2 inhibitor.
“Our presence at EADV demonstrates the significant progress across our dermatology portfolio,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “The late-breaking data from the STOP-HS clinical trial program reinforce the potential of povorcitinib to benefit patients impacted by hidradenitis suppurativa, a challenging and debilitating immune-mediated dermatologic condition. Data on ruxolitinib cream in new patient populations continues to demonstrate safety and efficacy in individuals with atopic dermatitis, vitiligo and prurigo nodularis.”
Key abstracts include:
- Hidradenitis Suppurativa: Phase 3 interim results from the STOP-HS program evaluating povorcitinib in moderate to severe cases (Sept. 17).
- Prurigo Nodularis: Pooled efficacy and safety data for ruxolitinib cream from the Phase 3 TRuE-PN1 and TRuE-PN2 studies (Sept. 17).
- Vitiligo: Findings on vitiligo-associated hearing loss in patients from a Phase 2 povorcitinib trial (Sept. 18).
- Atopic Dermatitis: Poster data showing long-term disease control with ruxolitinib cream in pediatric patients.
- Vitiligo: Additional posters covering lesion distribution, genital vitiligo, and combined therapy with NB-UVB phototherapy.
- Multiple Indications: Long-term safety analyses of ruxolitinib cream across seven Phase 3 trials in atopic dermatitis and nonsegmental vitiligo.
Incyte’s expanded slate of presentations reflects its strategic focus on immune-mediated dermatologic conditions and its push to bring new treatment options to patients across multiple indications.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.